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Antidepressant prescribing in Irish children:
secular trends and international comparison in
the context of a safety warning
K. O’Sullivan1*, F. Boland1, U. Reulbach1,2, N. Motterlini1ˆ, D. Kelly2, K. Bennett3 and T. Fahey1
Abstract
Background: In 2003, the Irish Medicines Board (IMB) warned against the treatment of childhood depression with
selective serotonin reuptake inhibitors (SSRIs) due to increased risk of suicide. This study examined the effect of this
warning on the prevalence of anti-depressants in Irish children and compared age and gender trends and
international comparisons of prescription rates.
Methods: A retrospective cohort study of the Irish Health Service Executive (HSE) pharmacy claims database for the
General Medical Services (GMS) scheme for dispensed medication. Data were obtained for 2002–2011 for those
aged ≤15 years. Prevalence of anti-depressants per 1000 eligible population, along with 95 % confidence intervals,
were calculated. A negative binomial regression analysis was used to investigate trends and compare rates across
years, sex and age groups (0–4, 5–11, 12–15 years). International prescribing data were retrieved from the literature.
Results: The prevalence of anti-depressants decreased from 4.74/1000 population (95 % CI: 4.47-5.01) in 2002 to
2.61/1000 population (95 % CI: 2.43-2.80) in 2008. SSRI rates decreased from 2002 to 2008. Prescription rates for
contra-indicated SSRIs paroxetine, sertraline and citralopram decreased significantly from 2002 to 2005, and, apart
from paroxetine, only small fluctuations were seen from 2005 onwards. Fluoxetine was the most frequently
prescribed anti-depressant and rates increased between 2002 and 2011. Anti-depressant rates were higher for
younger boys and older girls. The Irish prevalence was lower than the US, similar to the U.K. and higher than
Germany and Denmark.
Conclusions: The direction and timing of these trends suggest that medical practitioners followed the IMB advice.
Keywords: Children, Anti-depressants, Paediatric prescribing, Safety warning
Background
Depression is common in young people and contributes
to a variety of negative outcomes such as poor academic
attainment, difficulty in peer and family relations, and
increased risk of suicide [1]. Major depressive disorder
has a lifetime prevalence of 20.7 % in adults [1, 2]; and
affects up to 10 % of children [3]. Common symptoms
of depression in childhood include low mood, loss of
interest in once enjoyed activities, psychosomatic symp-
toms and in severe cases thoughts of suicide [1].
Depression in childhood, if left untreated, is likely to
continue into adulthood and over time becomes increas-
ingly difficult to treat [4]. Childhood depression can last
for several months, is recurrent and is twice as likely to
be observed in teenage girls as teenage boys [5]. A
higher rate of depression in teenage girls has been asso-
ciated with hormonal changes related to puberty rather
than age related development [5].
Anti-depressants are often used to treat depression,
anxiety and other disorders in children and adolescents
[6]. The late 1990’s saw a steady increase in the use of
anti-depressants in children, fuelled primarily by the rise
in popularity of selective serotonin reuptake inhibitors
(SSRIs) [7–9]. This rise was influenced by two factors;
early studies showing their effectiveness in treating adult
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depression and drug trials that showed the ineffective-
ness of tryciclic anti-depressants in the treatment of
childhood depression [3]. Further support for their use
in childhood depression and anxiety came from early
randomised controlled trials (RCT) which showed high
levels of SSRI efficacy in comparison to placebo [7, 10, 11].
However, reviews of SSRI safety and efficacy in the
treatment of childhood depression later revealed they
were more harmful than what had been originally
reported [12, 13].
In 2003, the Food and Drug Administration (FDA) re-
quested that GlaxoSmithKline (GSK) provide the results
of all drug trials that had examined the efficacy of SSRIs
in the treatment of Major Depressive Disorder (MDD)
in children. This request followed the airing of a docu-
mentary which highlighted the side effects of Seroxat
(paroxetine) and the suppression of data reporting these
side effects by the pharmaceutical industry. In May
2003, the GSK report revealed an association with par-
oxetine and suicidal behaviour in children. Following
this, and other reports the FDA published an advisory
paper highlighting the increased risk of suicidal behav-
iour in children being treated with SSRIs. Later that year,
the Medicines and Health Regulatory Agency (MHRA)
issued a recommendation to withdraw the use of all
SSRIs in children with MDD, except for fluoxetine [12],
a move which was endorsed by the Irish Medical Board
(IMB). In late 2004, the FDA required that manufac-
turers add a black box warning to all SSRIs including
the risk of suicidal behaviours [13]. The SSRIs paroxe-
tine, sertraline and citralopram were contraindicated in
children for the treatment of depression following these
warnings. Since 2004 these warnings have been ex-
tended, the FDA increased the age bracket from 18 to
24 in 2007 and the IMB adapted the SSRI warning up to
the age of 25 in 2008 (see Table 1) [14].
Increased rates in psychotropic drug prescribing in
children have been reported in recent times [15–19],
and anti-depressants are often the most frequently
prescribed [15–17]. While studies have shown that
prevalence of anti-depressants declined immediately
following the introduction of the FDA boxed warn-
ings [6, 20], there is evidence to suggest that this
decline was not sustained and that the prevalence of
paediatric anti-depressant prescribing is on the rise
[21]. Furthermore, there is wide variability across
countries in the use of anti-depressant medication for
children. For example, in 2000 in the US, the preva-
lence was 15 times greater than that of Germany, and
the rate in Germany was 9 times greater than that in
Denmark [9]. These differences are thought to be due
to several factors; including differences in diagnostic
criteria, treatment guidelines, drug regulations and
healthcare systems [9].
The aims of the current study are (i) to examine
whether the introduction of the IMB warnings was asso-
ciated with a reduction in overall and specific prevalence
of anti-depressants in Irish children, and (ii) to establish
whether the effect of this warning was maintained. Age
and gender trends were also considered, and addition-
ally, the prevalence of anti-depressants in children in
Ireland was compared to international studies.
Methods
Study population and study design
Data was obtained from the Irish General Medical
Services (GMS) scheme pharmacy claims database from
the Health Service Executive (HSE) – Primary Care
Table 1 Summary of the history of SSRI warnings across countries and agencies
Year, Month Country Agency Action
2003, May - GlaxoSmithKline Reported to FDA increased suicidal behaviour associated with paroxetine
2003, June U.K. MHRAa Paroxetine contraindicated in <18 s
2003, September U.K. MHRA Venflaxine contraindicated in <18 s
2003, October U.S. FDAb Advice paper published stating preliminary data suggests increased suicidal
behaviour associated with SSRIs
2003, December U.K. MHRA Contraindicate all SSRIs in <18 s apart from Prozac (fluoxetine)
2003, December Ireland IMBc Endorses MHRA warning for Ireland
2004, February U.S. FDA Commissioned advisory committee
2004, October U.S. FDA Issued black box warning relating to all anti-depressants <18 s
2005, August Europe EMEAd Issued warning against SSRIs in <18 s
2005, November Ireland IMB Reissued warning and updated label guidelines
2007, May U.S. FDA Increased age of risk of SSRIs to 24 years
2008, September Ireland IMB Warnings adapted up to age 25
aMedicines & Health Regulatory Agency bFood & Drug Administration c Irish Medicines Board dEuropean Medicines Agency
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Reimbursement Services (PCRS). The database contains
basic demographic information and details of dispensed
medications (coded using WHO’s [20] Anatomical Thera-
peutic Chemical (ATC) classification) for each individual
on the GMS scheme. The scheme is means tested and
provides free health services to those who are unable
to afford them. It represents approximately 28 % of
Irish children but over-represents socially deprived
populations. Data is freely available but with the
necessary confidentiality agreements. Permission was
given by the data controller to use the GMS dataset
if anonymised and analysed at group level. Therefore,
it was unnecessary to seek specific ethical approval
for this study.
All anti-depressant medication prescriptions (N06A;
classified according to the ATC classification system)
were extracted from the GMS database for children aged
0–15 years inclusive for the years 2002–2011.
Data analysis
The yearly prevalence of anti-depressants per 1000 GMS
population and associated 95 % confidence intervals for
children aged 0–15 years were calculated as a proportion
of all eligible children (0–15 years) entitled to free health
services, as identified from the annual reports produced
by the PCRS. The prevalence per 1000 GMS eligible
population and associated 95 % confidence intervals
(CIs) were also calculated across years (2002–2011), age
groups (0–4 years, 5–11 years and 12–15 years) and
gender.
A negative binomial regression model was used to
determine trends in prevalence. The log of the GMS
population was used as the offset term and year, age
group, gender and all possible interactions between
these variables were included as fixed effects in the
model. The Bonferroni method was used to control
the overall Type I error rate in making multiple com-
parisons of means and p-values <0.05 were deemed
significant.
Data analyses was performed using Stata version 11
(StataCorp, College Station, Tx, USA) and SAS version
9.3 (SAS Institute Inc. Cary, NC, USA).
Comparison studies
Comparison studies, examining the prevalence of anti-
depressants in paediatric populations, were identified
from a search of published literature from 1995 – 2013.
Articles were included if they reported the prevalence of
anti-depressants in a community setting and provided
overall prevalence. Studies which reported overall per-
centage prevalence were transformed to per 1000 popu-
lation to facilitate comparison.
Results
Population sample
During the study period, January 2002 to December
2011, the number of children ≤15 years in Ireland, as
identified from the HSE-PCRS pharmacy database,
ranged between 188,833 and 311,579. On average, 51 % of
the study population were male and 49 % were female.
Prescribing trends
Table 2 shows the prevalence of anti-depressants for
2002–2011. In 2002, 4.74/1000 population (95 % CI:
4.47-5.01) received at least one anti-depressant medica-
tion prescription and this decreased yearly to 2.61/1000
population (95 % CI: 2.43-2.80) in 2008. Between 2008
and 2011 the prevalence fluctuated slightly.
During the study period the prevalence of SSRIs was
much higher than non-SSRIs (Fig. 1). There were no
significant differences in the prevalence of SSRIs be-
tween 2002 and 2003. However, a significant decrease
was seen between 2003 and 2004, and 2003 and 2005;
the period directly following the IMB warning. Since
2005, the prevalence of SSRIs has remained relatively
stable.
Fluoxetine was the most frequently prescribed anti-
depressant (Fig. 2), and although no significant differences
were seen, the prevalence of fluoxetine increased between
2002 and 2011. Over the study period a decrease in the
prevalence of contra-indicated anti-depressants was seen.
The prevalence of paroxetine decreased significantly from
1.00/1000 population (95 % CI: 0.88-1.13) in 2002 to 0.03/
1000 population (95 % CI: 0.02-0.05) in 2011. Significant
decreases were observed yearly from 2002 through to
2007. From 2007 onwards, the prevalence stabilised. The
prevalence of citalopram also decreased significantly over
the study period from 0.87/1000 population (95 % CI:
0.75-0.98) in 2002 to 0.19/1000 population (95 % CI: 0.14-
0.23) in 2011. The prevalence of sertraline and escitalo-
pram, after its introduction to the market in 2002,
Table 2 Prevalence and 95 % confidence intervals of
anti-depressants to children aged 0–15 years from 2002–2011
Year Prevalence per 1,000 GMS population (95 % confidence interval)
2002 4.74 (4.47–5.01)
2003 4.33 (4.07–4.59)
2004 3.86 (3.62–4.11)
2005 3.51 (3.27–3.74)
2006 3.09 (2.87–3.30)
2007 2.72 (2.52–2.91)
2008 2.61 (2.43–2.80)
2009 2.71 (2.54–2.89)
2010 2.63 (2.47–2.80)
2011 2.86 (2.69–3.03)
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fluctuated over the study period (Fig. 2). For sertraline,
significant decreases between 2004 and 2006, and 2004
and 2007 were observed.
Gender and Age
Figure 3 shows the prevalence of anti-depressants for all
years for males and females and all age groups (0–4
years, 5–11 years and 12–15 years). The fixed interactions
year × gender × age group (p = 0.93) and year × gender
(p = 0.35) were not significant while the interactions
age group × year (p < 0.0001) and age group × gender
(p < 0.0001) were significant. This means that the
effect of age group on the prevalence of anti-
depressants differed over years and differed for males
and females also.
The least square means and t-tests for the difference
in prevalence of anti-depressants between age groups for
gender and years showed that significant differences
existed between males and females for all age groups
whereby males had higher prevalences at 0–4, and 5–11
age groups. Females had higher rates in the 12–15 year
age group. Additionally, for all years, significantly higher
prevalences were seen for the 12–15 year age group
compared to the 0–4 year, and the 5–11 year groups.
Fig. 1 Prevalence of SSRIs (N06AB) vs non-SSRIs (N06AA, N06AF, N06AG, N06AX) per 1000 GMS population aged 0–15 years old from 2002 to 2011
Fig. 2 Prevalence of SSRIs per 1000 GMS population aged 0–15 years old from 2002 to 2011 (including when warnings were introduced)
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Overall significantly higher prevalences were seen for
the 5–11 year age group compared to the 0–4 year
group for 2002, 2004, 2005 and 2006 only.
Comparison studies
Studies examining the overall prevalence and incidence
of anti-depressants in paediatric populations in a com-
munity setting were identified (Table 3). Studies from
Netherlands [21], the US [22], UK [11], Germany [23],
and Denmark [24] were included.
The overall prevalence of anti-depressants for the
study period was 3.3/1000 population. Only one country
reported a higher overall prevalence, the US study con-
ducted between 2002 and 2005 (8.77/1000 population)
[22]. Table 3 shows that the prevalence of anti-depressants
in paediatrics varies substantially with Ireland ranked
higher than the majority of comparison countries. How-
ever, there are differences across the different studies in
terms of age groups, sample size and year the data were
assessed.
Discussion
The study observed that SSRI prescription rates reduced
significantly following the introduction of the IMB warn-
ing. It showed that paroxetine rates reduced from 2002
onwards, which may indicate the influence of media
coverage on Irish prescribing. Results show that adoles-
cent girls are more likely to receive a prescription of
anti-depressants than adolescent boys and the overall
prevalence of anti-depressants in 0–15 year olds in
Ireland lies close to the median value in comparison to
international studies.
An overall reduction in the prevalence of SSRIs and all
anti-depressants in children over the study period was
seen. These reductions appear to be influenced by the
IMB and MHRA regulatory recommendations of 2003.
Higher rates of fluoxetine prescribing further supports
Fig. 3 Trends in the prevalence of anti-depressants for 2002–2011, classified by gender and age group
Table 3 Characteristics of studies included for comparative data and comparison of average prescribing rates per 1000 GMS
children between 2001 and 2011, to European rates per 1000 children
Study (publication year) Country
(year data represents)
Sample Size Age Overall Rate of Anti-depressant
Prescribing (per 1000)
Setting
Dorks (2013) [23] Germany (2004–2006) 2 599 685 0–17 1.7/1000 Pharmaco-epidemiology database
Volkers (2007) [24] Netherlands
(2001–2005)
350 000 0–17 2.2/1000 Information Network of General Practice
Wijlaars (2012) [12] UK (1995–2009) 1 502 753 0–17 3.6/1000 UK primary care database
Parkinson (2012) [25] US (2002–2005) 32 111 0–17 8.77/1000 Medical Expenditure Panel survey
Steinhausen (2014) [26] Denmark (1996–2010) 105 908 0–17 1.6/1000 National Patient Database
GMS data Ireland (2002 – 2011) 311 579 0–15 3.3/1000 Primary care reimbursement service
pharmacy claims
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this. The MHRA deemed fluoxetine an acceptable treat-
ment of MDD in children, a stance which was adopted
by the IMB. Interestingly, the prevalence of fluoxetine
increases from 2002 to 2011. This suggests that while
the prevalence of SSRIs decreased over time, the
prevalence of fluoxetine, in Ireland, was not affected
by the general black box warning placed on all SSRIs
by the FDA.
In addition to an overall reduction in the prevalence of
anti-depressants, the study observed a significant reduc-
tion in the prevalence of contra-indicated anti-depressants
- paroxetine and citralopram and to some extent sertra-
line. This decrease, coupled with the increase of fluoxetine
prescribing, suggests a possible link between the IMB
warning and prescription practices. The decrease in citra-
lopram began in 2003, the year the warning was issued.
The decline in paroxetine use was more pronounced than
the other SSRIs and began in 2002, prior to the IMB
warnings [25].
Since 2005 the prevalence of SSRIs in children on the
GMS has remained relatively stable (2.1/1000 popula-
tion). While not significant, the prevalence increased in
the latter part of the study period. This may indicate that
concerns about the risks associated with SSRIs have dis-
sipated in recent years. This may be due to contradic-
tions that exist in recent literature regarding the safety
and efficacy of SSRIs. For example, some studies report
no increased risk of suicidality following SSRI prescrip-
tions in childhood [26] and others suggest that a rela-
tionship exists between decreases in the prevalence of
SSRIs and increases in suicide behaviour among young
people [27]. Contrary to this view a recent review of
published and unpublished SSRI research revealed sig-
nificant increases in suicidal behaviour in children taking
contraindicated SSRIs [12–14, 28, 29].
Age and gender analysis revealed that before adoles-
cence (<12 years of age), boys were more likely to be
prescribed an anti-depressant than girls. This trend re-
versed after age 12 where significantly more girls re-
ceived an anti-depressant prescription than boys. This
finding is in line with previous research, whereby pre-
pubescent boys show higher rates of anti-depressant pre-
scriptions than prepubescent girls [11], and adolescent
girls show higher rates of anti-depressant prescriptions
than adolescent boys [11, 21, 24]. Research shows that
girls aged 3–13 years are less likely than boys to be diag-
nosed with major depression and girls age 12–17 are
more likely to meet the diagnostic criteria of major de-
pression than boys [11]. Age trends reveal that older
children (12–15 age groups) are more likely to be pre-
scribed an anti-depressant than both younger age
groups. This is consistent with previous research which
shows that the rate of anti-depressant and overall psy-
chotropic prescriptions increases with age [18, 27].
The prevalence of anti-depressants in the current
study are similar in size and trend to those found in the
UK primary care database which examined prevalence
from 1995 to 2009 [11]. They found a reduction of SSRI
rates following the FDA warning. However, of the
contra-indicated SSRIs only paroxetine showed a signifi-
cant decrease following 2003; citralopram and sertraline
were not affected. This difference in contra-indicated
prescription trends may be a consequence of methodo-
logical differences between our study and the UK study.
Our study examined year on year prescription rates,
whereas the UK study looked at 3 time periods (1995 –
2002, 2003–2005, and 2006–2009).
While the overall prevalence for the current study was
similar to the UK, it was higher than Germany, the
Netherlands and Denmark. Denmark showed the smal-
lest overall prevalence and the Danish prescribing trends
did not seem to be affected by the FDA warning. The
rates in the US study were twice the rate of our study,
which is in line with previous research findings [17]. The
differences in prescription trends may be due to high
levels of heterogeneity between the studies, cultural vari-
ation in prescription practices and differences in the
availability of other treatments options [28].
Limitations
The HSE-PCRS GMS pharmacy claims database repre-
sents approximately one-third of Irish children and
over-represents more socially disadvantaged children in
the Irish population. This may result in an over-
estimation of the true trends in the prevalence of anti-
depressants, given that children from lower socioeco-
nomic backgrounds are more likely to be prescribed a
psychotropic medication [29, 30] and are at greater risk
of depression [11] and anxiety related disorders [31].
Direct comparison of international prevalence for low
socioeconomic populations was limited; however studies
that have included deprivation as an indicator of preva-
lence show that as deprivation increases the prevalence
of anti-depressants increases also [11].
The GMS data set does not collect information about
the indication for prescriptions or about the setting in
which the prescription was initiated (e.g. primary care,
hospital or specialist setting). In addition, there are no
national rates of childhood depression available in
Ireland to compare current prescription rates to. This
lack of diagnostic information makes it difficult to know
whether the current rates reflect treatment of depres-
sion, or other conditions (obsessive compulsive disorder
(OCD) or anxiety). We know that cultural differences
exist in terms of what indications anti-depressants are
prescribed for. For example, in the US they are often
prescribed for depression and ADHD, whereas in Europe
OCD and depression are most likely to receive an anti-
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depressant prescription [17]. The current data does not
allow us to explore the indications for which anti-
depressants are most commonly prescribed in Irish chil-
dren. Furthermore, there is no data on dispensing and
treatment compliance; hence the current rate may not
accurately reflect actual anti-depressant use.
Conclusions
After 2003, a significant decrease in the prevalence of
SSRIs in children, particularly paroxetine and citralo-
pram, was found. The prevalence of fluoxetine remained
stable and increased from 2002 to 2011. The direction
and timing of these trends suggest that medical practi-
tioners followed the FDA and CSM advice, although the
earlier reduction of paroxetine would suggest that the
negative media attention had an influence on prevalence,
though it is unknown whether this effect was patient or
practitioner driven.
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